Randomized Trialhigh evidence

Vorasidenib in IDH1-mutant or IDH2-mutant low-grade glioma (INDIGO): secondary and exploratory endpoints from a randomised, double-blind, placebo-controlled, phase 3 trial.

The Lancet. Oncology·December 1, 2025·PMID 41175888

Why it matters

Vorasidenib is the first targeted therapy to show robust clinical benefit in low-grade IDH-mutant gliomas, offering a non-cytotoxic option that delays radiation and chemotherapy while preserving function.

Infographic summary of Vorasidenib in IDH1-mutant or IDH2-mutant low-grade glioma (INDIGO): secondary and exploratory endpoints from a randomised, double-blind, placebo-controlled, phase 3 trial.
Visual abstract · MedLit

The papers that matter, first.

MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.

§

MedLit · Evidence, Distilled